Navigation Links
ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes - Expected Launch in Q2 2012
Date:12/15/2011

YOKOHAMA, Japan, December 15, 2011 /PRNewswire/ --

ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today that the company licensed worldwide right to commercialize hepatocytes derived from human iPS (induced pluripotent stem) cells. ReproCELL has been collaborating with the National Institute of Biomedical Innovation (NIBIO; Director General: Koichi Yamanishi; Osaka, Japan) to establish an effective in-vitro drug screening for hepatic toxicity and liver metabolism using hepatocytes derived from human iPS cells since early this year.

Together with NIBIO, the company successfully established the hepatocytes which highly express active drug metabolizing enzyme. Currently, the company is evaluating the system using various drugs with pharmaceutical companies to observe how the drugs are metabolized.  ReproCELL is anticipating its commercialization in Q2 2012. Prior to the launch, sample of the cells will become available for testing to pharmaceutical and biotech companies in January 2012.

ReproCELL is a world-leading pioneer in commercializing human pluripotent stem cells as an effective tool for drug discovery and development. The company has successfully launched iPS cell derived cardiomyocytes in April 2009 for cardiac toxicity testing, followed by the launch of iPS cell derived neuronal cells in October 2010 for efficacy screening of neuroactive compounds.

ReproCELL's Representative Director and CEO, Chikafumi Yokoyama PhD commented, "We are pleased to see iPS cell-derived hepatocytes showing the highest level of quality ever seen, expressing the same qualities as that of primary human hepatocytes currently used by the pharmaceutical industry, including drug metabolizing enzyme activity. We can expect to see its early adoption for drug toxicity and pharmacokinetic studies."

Aspects of NIBIO's technology on the induction of iPS cell-derived hepatocyte differentiation can be found in the following publication:

Efficient Generation of Functional Hepatocytes From Human Embryonic Stem Cells and Induced Pluripotent Stem Cells by HNF4α Transduction.

Takayama K, Inamura M, Kawabata K, Katayama K, Higuchi M, Tashiro K, Nonaka A, Sakurai F, Hayakawa T, Kusuda Furue M, Mizuguchi H., Mol Ther. 2011 Nov 8. [Epub ahead of print] PMID: 22068426

Company:  ReproCELL Inc.
Representative: Chikafumi Yokoyama PhD,
Contact:  info_repro@reprocell.com   Tel:+81-(0)45-475-3887
KDX Shin-Yokohama 381 bldg. 8F, 3-8-11 Shin-Yokohama, Kohoku-ku,
Yokohama, Kanagawa 222-0033, Japan



'/>"/>
SOURCE ReproCELL Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells
2. SK Life Sciences has Licensed Pristima
3. NeoStem Featured on CBS2 News; Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems; Procedure to be Used by NeoStem Affiliate in China
4. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
5. Full Agenda Announced for CMAC 2011 - CBIS 2nd Annual Commercialization and Market Access Congress
6. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
7. Larta Institute Receives Award for National Institutes of Health Commercialization Assistance Program at 2011 Acquisition, Grants, and Small Business Symposium
8. Saladax Biomedical, Inc. Announces European Commercialization Team
9. Reportlinker Adds Top & Emerging Bio-Fuel Markets by Technology, Feedstocks, Regulations, Pricing & Commercialization Trends & Forecasts (2011 - 2016)
10. Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program
11. Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building ... corporate rebranding initiative announced today. The bold new look is part of a ... company moves into a significant growth period. , It will also expand its service ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... Dr. Bob ... at his local San Diego Rotary Club. The event entitled “Stem ... CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two ...
(Date:10/10/2017)... BARBARA, CALIFORNIA (PRWEB) , ... October 10, 2017 ... ... management, technological innovation and business process optimization firm for the life sciences and ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation ...
(Date:10/9/2017)... ... 2017 , ... The award-winning American Farmer television series will feature 3 Bar ... Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ten billion ... continue to feed a growing nation. At the same time, many of our valuable ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):